Sonoma Pharmaceuticals (SNOA) to Post Quarterly Earnings on Thursday

Sonoma Pharmaceuticals (NASDAQ:SNOA) is expected to be releasing its results before the market opens on Thursday, August 6th. Analysts expect Sonoma Pharmaceuticals to announce earnings of ($0.30) per share and revenue of $4.99 million for the quarter.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings results on Tuesday, June 16th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.09). The business had revenue of $5.56 million during the quarter, compared to analyst estimates of $5.57 million. Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.

Sonoma Pharmaceuticals Stock Up 7.1%

Shares of SNOA opened at $1.20 on Wednesday. The company has a 50-day moving average price of $1.17 and a two-hundred day moving average price of $1.92. The stock has a market cap of $5.75 million, a price-to-earnings ratio of -0.63 and a beta of 1.28. Sonoma Pharmaceuticals has a 12 month low of $0.85 and a 12 month high of $6.92.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently raised its stake in Sonoma Pharmaceuticals stock. DRW Securities LLC lifted its holdings in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the period. DRW Securities LLC owned 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent reporting period. 1.95% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a report on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Sonoma Pharmaceuticals has an average rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.